Literature DB >> 12430677

Positive (1-->3)-beta-D-glucan in blood components and release of (1-->3)-beta-D-glucan from depth-type membrane filters for blood processing.

Makoto Usami1, Atsushi Ohata, Takeshi Horiuchi, Koichi Nagasawa, Toshio Wakabayashi, Shigenori Tanaka.   

Abstract

BACKGROUND: The false-positive elevation of plasma (1-->3)-beta-D-glucan level, a serodiagnostic test for deep-seated mycosis, is suspected in patients administered with blood components. STUDY DESIGN AND METHODS: (1-->3)-beta-D-Glucan and endotoxin levels in blood components consisting of 12 albumins, 8 immunoglobulins, and 3 blood coagulation factors were measured by fungal infection tests (Fungitec G-test, Seikagaku Co.; the Wako WB003 test, Wako Pure Chemical Industries; and the Endospec ES test, Seikagaku Co.). In vitro release of (1-->3)-beta-D-glucan from the depth-type filters made by cellulose membrane to process blood components was analyzed through an in vitro filtration process as a source of (1-->3)-beta-D-glucan in blood components.
RESULTS: The amounts of (1-->3)-beta-D-glucan in blood components ranged from 0 to 7510 pg per mL in the Fungitec G-test, with wide variations among brands. The positive rates over 20 pg per mL were 75 percent in albumin solutions, 40 percent in blood coagulation factors, and 63 percent in immunoglobulin solutions. (1-->3)-beta-D-Glucan levels released from the five depth filters ranged from 5 to 2516 pg per mL. The (1-->3)-beta-D-glucan level in filtration fluid was decreased by rinsing with distilled water, but rebounded again during the albumin filtration process.
CONCLUSION: Depth filters are considered the source of (1-->3)-beta-D-glucan content in some blood components.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12430677     DOI: 10.1046/j.1537-2995.2002.00162.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  22 in total

1.  False-positive plasma (1-->3)-beta-D-glucan test following immunoglobulin product replacement in an adult bone marrow recipient.

Authors:  Masahiro Ogawa; Hiroki Hori; Shigeko Niiguchi; Eiichi Azuma; Yoshihiro Komada
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

2.  How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors.

Authors:  H Hammarström; N Kondori; V Friman; C Wennerås
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-09       Impact factor: 3.267

3.  The EMPIRICUS trial-the final nail in the coffin of empirical antifungal therapy in the intensive care unit?

Authors:  Michael Osthoff; Nina Khanna; Martin Siegemund
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 4.  Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis.

Authors:  James A Grubbs; John W Baddley
Journal:  Curr Rheumatol Rep       Date:  2014-10       Impact factor: 4.592

5.  Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections.

Authors:  Jerry W Pickering; Howard W Sant; Catherine A P Bowles; William L Roberts; Gail L Woods
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

6.  Usefulness of 1,3 Beta-D-Glucan Detection in non-HIV Immunocompromised Mechanical Ventilated Critically Ill Patients with ARDS and Suspected Pneumocystis jirovecii Pneumonia.

Authors:  Tobias Lahmer; Clarissa Prazeres da Costa; Jürgen Held; Sebastian Rasch; Ursula Ehmer; Roland M Schmid; Wolfgang Huber
Journal:  Mycopathologia       Date:  2017-04-04       Impact factor: 2.574

7.  Reactivity of (1-->3)-beta-d-glucan assay with commonly used intravenous antimicrobials.

Authors:  Francisco M Marty; Colleen M Lowry; Steven J Lempitski; David W Kubiak; Malcolm A Finkelman; Lindsey R Baden
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

8.  Point-Counterpoint: Should Serum β-d-Glucan Testing Be Used for the Diagnosis of Pneumocystis jirovecii Pneumonia?

Authors:  Gabriela Corsi-Vasquez; Luis Ostrosky-Zeichner; Edward F Pilkington; Paul E Sax
Journal:  J Clin Microbiol       Date:  2019-12-23       Impact factor: 5.948

9.  Quantification of 1,3-beta-D-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting.

Authors:  P Brian Smith; Daniel K Benjamin; Barbara D Alexander; Melissa D Johnson; Malcolm A Finkelman; William J Steinbach
Journal:  Clin Vaccine Immunol       Date:  2007-05-30

10.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.